Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11901312rdf:typepubmed:Citationlld:pubmed
pubmed-article:11901312lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:11901312lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:11901312lifeskim:mentionsumls-concept:C0302809lld:lifeskim
pubmed-article:11901312lifeskim:mentionsumls-concept:C0010927lld:lifeskim
pubmed-article:11901312lifeskim:mentionsumls-concept:C0017710lld:lifeskim
pubmed-article:11901312lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:11901312pubmed:issue2lld:pubmed
pubmed-article:11901312pubmed:dateCreated2002-3-19lld:pubmed
pubmed-article:11901312pubmed:abstractTextDacarbazine (DTIC) is commonly used for the treatment of malignant melanoma and Hodgkin's disease. A very rare complication of this cytotoxic agent is acute vascular hepatic damage, e.g. veno-occlusive disease or Budd-Chiari syndrome. The pathophysiological mechanism involved seems to be an immune reaction. This complication is frequently fatal. We report a patient who developed severe hepatic failure following DTIC treatment who responded favorably to treatment with glucocorticosteroid.lld:pubmed
pubmed-article:11901312pubmed:languageenglld:pubmed
pubmed-article:11901312pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11901312pubmed:citationSubsetIMlld:pubmed
pubmed-article:11901312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11901312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11901312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11901312pubmed:statusMEDLINElld:pubmed
pubmed-article:11901312pubmed:monthFeblld:pubmed
pubmed-article:11901312pubmed:issn0959-4973lld:pubmed
pubmed-article:11901312pubmed:authorpubmed-author:LishnerMichae...lld:pubmed
pubmed-article:11901312pubmed:authorpubmed-author:HerishanuYair...lld:pubmed
pubmed-article:11901312pubmed:authorpubmed-author:Kitay-CohenYo...lld:pubmed
pubmed-article:11901312pubmed:issnTypePrintlld:pubmed
pubmed-article:11901312pubmed:volume13lld:pubmed
pubmed-article:11901312pubmed:ownerNLMlld:pubmed
pubmed-article:11901312pubmed:authorsCompleteYlld:pubmed
pubmed-article:11901312pubmed:pagination177-9lld:pubmed
pubmed-article:11901312pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:meshHeadingpubmed-meshheading:11901312...lld:pubmed
pubmed-article:11901312pubmed:year2002lld:pubmed
pubmed-article:11901312pubmed:articleTitleThe role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.lld:pubmed
pubmed-article:11901312pubmed:affiliationDepartment of Medicine A and Liver Clinic-Meir Hospital, Kfar-Saba and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.lld:pubmed
pubmed-article:11901312pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11901312pubmed:publicationTypeCase Reportslld:pubmed